Tag: IgAN
FDA grants Otsuka’s Sibeprenlimab breakthrough therapy designation in IgAN
In a significant development for the treatment of kidney disease, the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sibeprenlimab, an ... Read More
Calliditas Therapeutics bags TARPEYO FDA approval for IgAN
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) has announced a landmark FDA approval for TARPEYO (budesonide) delayed release capsules, aimed at reducing kidney function ... Read More
Novartis to expand renal portfolio with Chinook Therapeutics acquisition
Novartis has announced its agreement to acquire Chinook Therapeutics, a clinical stage biopharmaceutical company based in Seattle, Washington in a deal worth up to around ... Read More
Chinook Therapeutics gets orphan drug status from EC for atrasentan in IgAN
Chinook Therapeutics, a US-based biopharma company, has secured orphan drug designation for atrasentan from the European Commission (EC) for the treatment of primary IgA nephropathy ... Read More